Roche: Nine-month Sales 2016 Presentation (Roche) - Oct 22, 2016 - Anticipated first patient for all-comer population in P3 IMpower 110 trial (NCT02409342) of Tecentriq monotherapy for adjuvant NSCLC in Q4 2016; Anticipated first patient in arm D of P1 trial (NCT02715531) of Tecentriq + Avastin/vanucizumab in HCC in Q4 2016; Anticipated first patient in P1/2 trial (NCT02729896) of Tecentriq + Rituxan + polatuzumab for DLBCL in Q1 2017
Trial status • Biosimilar • Diffuse Large B Cell Lymphoma • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Non Small Cell Lung Cancer • Non-Hodgkin's Lymphoma • Oncology
|